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Abstract
Background: Coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) in HIV-infected patients receiving a
commonly used nevirapine-based antiretroviral therapy is a major concern for African clinicians owing to its high
prevalence, the infrequent testing and treatment of viral hepatitis, and the impact of liver disease on the
tolerability and effectiveness of anti-HIV treatment. We compared the hepatotoxicity and the immunological,
virological and clinical effectiveness of a nevirapine-based antiretroviral therapy between patients infected with HIV
only and patients coinfected with hepatitis B or C virus in Cameroon.
Methods: A retrospective cohort study was conducted among HIV-1-infected patients. Plasma HBV DNA and HCV
RNA were tested in positive or indeterminate samples for HBsAg or HCV antibodies, respectively. All patients
received nevirapine and lamivudine plus stavudine or zidovudine.
Results: Of 169 HIV-1-infected patients with a median baseline CD4 count of 135 cells/mm
3 (interquartile range
[IQR] 67-218), 21% were coinfected with HBV or HCV. In coinfected patients, the median viral load was 2.47 × 10
7
IU/mL for HBV (IQR 3680-1.59 × 10
8) and 928 000 IU/mL for HCV (IQR 178 400-2.06 × 10
6). Multivariate analyses
showed that the risk of hepatotoxicity was 2-fold higher in coinfected patients (p < 0.01). The response to
antiretroviral therapy was however comparable between monoinfected and coinfected patients in terms of CD4
cell count increase (p = 0.8), HIV-1 viral load below 400 copies/mL (p = 0.9), death (p = 0.3) and death or new
AIDS-defining event (p = 0.1). Nevirapine was replaced by a protease inhibitor in 4 patients owing to
hepatotoxicity.
Conclusion: This study suggests that the nevirapine-based antiretroviral therapy could be used safely as first-line
treatment in patients with low CD4 cell count in Africa despite frequent coinfections with HBV or HCV and
infrequent testing of these infections. Although testing for HBV and HCV should be systematically performed
before initiating antiretroviral therapy, transaminases elevations at baseline or during treatment should be a
decisive argument for testing when hepatitis status is unknown.
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Coinfection with hepatitis B virus (HBV) or hepatitis
C virus (HCV) in HIV-infected patients receiving a
nevirapine-based antiretroviral therapy is a major con-
cern for African clinicians owing to its high preva-
lence, the infrequent testing and treatment of viral
hepatitis, and the impact of liver disease on the toler-
ability and effectiveness of anti-HIV treatment [1].
While HIV-related morbidity and mortality are
decreasing thanks to the scaling-up of antiretroviral
therapy, the impact of liver disease is likely to
increase in Africa. In addition, initiation of antiretro-
viral therapy has been suggested in all patients coin-
fected with HIV and hepatitis B or C virus
irrespective of the CD4 cell count.
Nevirapine, the non nucleosidic reverse transcriptase
inhibitor (NNRTI) most often used in first-line treat-
ment in combination with two nucleosidic reverse tran-
scriptase inhibitors, is associated with early
hypersensitivity reactions (generally in the first 12 weeks
after treatment initiation) which can cause fulminant
hepatitis leading to hepatic failure and death, and with
later onset of direct drug-related hepatotoxicity leading
to liver enzymes elevations [2]. The risk of hepatotoxi-
city is increased in patients coinfected with HBV or
HCV [3-5]. The World Health Organization (WHO)
therefore recommends to use nevirapine with caution
and regular monitoring in patients who have baseline
grade 1, 2 or 3 elevations of liver enzymes and positive
or unknown HBV or HCV testing [6]. In addition, nevir-
apine is not recommended in patients with a grade 4
elevation of liver enzymes.
The impact of HBV or HCV coinfection on the effec-
tiveness of a nevirapine-based antiretroviral therapy
remains unclear owing to the lack of specific studies
especially in the African context. A recent South African
study in HBV-coinfected patients receiving the less
hepatotoxic efavirenz (the second NNRTI used in first-
line treatment) found similar response to antiretroviral
therapy between monoinfected and coinfected patients
despite higher hepatotoxicity in the latter [7]. Regardless
of antiretroviral regimens (often not reported), studies
on HBV or HCV coinfection in Western and Asian
countries provided conflicting results with respect to
CD4 cell increase, HIV suppression, AIDS progression
and mortality [8-21].
We therefore compared the hepatotoxicity and the
immunological, virological and clinical effectiveness of
a nevirapine-based antiretroviral therapy between
patients infected with HIV only and patients coin-
fected with HIV and hepatitis B or C virus in Camer-
oon [22].
Methods
Study design
A retrospective cohort study was conducted in two
major hospitals (the Military Hospital and the Central
Hospital) in Yaoundé, the capital of Cameroon, among
HIV-1-infected patients enrolled from 2001 to 2003 in
two clinical research projects designed to assess antire-
troviral treatments [23-25]. The National Ethics Com-
mittee of Cameroon approved the study protocols, and
the patients gave their written informed consent. The
eligibility criteria, follow-up methods, medical and social
staff, and coordinators were similar in the two projects.
Briefly, patients over 18 years were eligible if they had
confirmed HIV-1 infection, AIDS or a CD4 count below
350 cells/mm
3, a Karnofsky score over 50%, and no con-
traindications to antiretroviral treatment, including
serum liver enzyme levels less than five times the upper
limit of normal (ULN) in the first project or less than
three times the ULN in the second project. All patients
received nevirapine and lamivudine plus stavudine or
zidovudine. Tenofovir was not available. Efavirenz was
temporarily substituted for nevirapine in case of conco-
mitant tuberculosis therapy. Care (visits and laboratory
exams) and drugs (antiretrovirals, and preventive and
curative treatments for opportunistic infections) were
provided free of charge.
Clinical and laboratory procedures
Hepatitis B and C markers were assessed on baseline
blood samples frozen at -80°C. Enzyme immunoassays
(EIA) were used to detect hepatitis B surface antigens
(HBsAg; Monolisa Ag HBs Plus, Bio-rad, Marnes la
coquette, France) and antibodies to hepatitis C virus
(anti-HCV; Ortho HCV EIA 3.0, Ortho-clinical Diagnos-
tics, Riratan, NJ, USA). Plasma HBV DNA and HCV
RNA were tested in positive or indeterminate samples for
HBsAg or anti-HCV, respectively, using the Cobas
Ampliprep/Cobas TaqMan quantitative assay (Roche
Diagnostics GmbH, Mannheim, Germany; quantification
r a n g eo f1 2t o2 . 2×1 0
8 IU/mL for HBV and 15 to 6.9 ×
10
7 IU/mL for HCV).
The CD4 cell counts were measured with a FACS-
Count device (Becton Dickinson, Mountain View, Cali-
fornia, USA) at baseline and then every 6 months. The
HIV-1 RNA load was determined using the Roche
Amplicor HIV-1 Monitor ass a y( R o c h eM o l e c u l a rS y s -
tems, Branchburg, New Jersey, USA) or the Bayer
bDNA HIV-1 Quantiplex assay (Bayer Diagnostics,
Emeryville, California, USA) at baseline, months 3 and
6, and then every 6 months. Serum liver enzymes (ala-
nine aminotransferase [ALT] and aspartate aminotrans-
ferase [AST]) levels were assayed at baseline, weeks 2, 4
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Page 2 of 11and 6, and then months 2, 3, 6, 9, 12, 18 and 24. Hepa-
totoxicity was graded with the French National Agency
for Research on AIDS and Viral Hepatitis (ANRS) toxi-
city scale in which an ALT or AST level of 1.25-2.5
times the ULN defines grade 1, >2.5-5 times the ULN
defines grade 2, >5-10 times the ULN defines grade 3
and >10 times the ULN defines grade 4 http://www.
anrs.fr/content/download/2242/12805/file/ANRS-Gra-
deEI-V1-En-2008.pdf. At each time point, hepatotoxicity
grade was defined on the basis of the higher value of
either ALT or AST. The HIV disease stage was deter-
mined according to the 1993 Centers for Disease Con-
trol and Prevention (CDC) classification.
Statistical analysis
Patients were classified as coinfected if they had positive
HBV DNA or HCV RNA. The analyses were based on
an intention-to-treat approach. Data were censored at
the time of each patient’s month 24 visit or, if follow-up
was shorter, at the time of the last visit or death. The c
2
test and, when sample sizes were too small, Fisher’s
exact test were used to compare the distribution of cate-
gorical variables between the infection groups (HBV or
HCV-coinfected patients versus HIV-monoinfected
patients). For continuous variables, comparisons were
based on the non parametric Mann-Whitney two-sam-
ple test.
Hepatotoxicity was first assessed by using two end
points: 1) occurrence of at least one episode of grade 2
or higher hepatotoxicity, and 2) occurrence of at least
one episode of grade 3 or 4 hepatotoxicity. Kaplan-
Meier curves were plotted and differences between
monoinfected and coinfected patients were checked for
significance by the log-rank test. Cox proportional
hazard models were used to compare hepatotoxicity
between groups adjusted on baseline covariates. The
proportional hazards assumption was evaluated by both
graphic and statistical (based on Schoenfeld residuals)
methods. A multivariate Poisson regression was then
used to compare between groups the highest grade of
hepatotoxicity reached by each patient during follow-up.
The evolution of the CD4 cell count during follow-up
was estimated using a mixed-effect linear regression
model. Taking into account the biphasic evolution of
the CD4 cell count during antiretroviral therapy [26],
we allowed the slope to change after 6 months and
included a quadratic effect in the second phase. In order
to compare the CD4 cell counts evolution in monoin-
fected and coinfected patients, terms of interaction
between infection status and each phase’s slope or quad-
ratic effect were tested. The CD4 cell counts were
square root-transformed to approximate a normal distri-
bution. The time to reach a viral load below 400 copies/
mL, death, and death or new AIDS-defining event from
treatment initiation were compared between groups by
using multivariate Cox models.
Multivariate analyses were adjusted on the following
baseline covariates: gender (women versus men), age (≥
42 versus <42 years), time since diagnosis of HIV infec-
tion (<24 versus ≥ 24 months), body mass index (≥ 21
versus <21 kg/m
2), Karnofsky score (<100% versus
100%), CDC clinical stage, CD4 cell count (≥ 100 versus
<100 cells/mm
3), HIV-1 viral load (<5.0 versus ≥ 5.0
log10 copies/mL), hemoglobin level (≥ 10 versus <1 0g /
dL), total lymphocytes count (≥ 1700 versus < 1700
cells/mm
3), liver enzymes levels (≥ 1.25 versus <1 . 2 5×
ULN), antiretroviral therapy and cotrimoxazole prophy-
laxis. Independent covariates associated with outcomes
with a conservative p value of < 0.25 in univariate analy-
sis were subsequently tested in multivariate analysis.
A backward elimination procedure was used to deter-
mine the final model containing only the infection
group, together with significant covariates and potential
confounders. The incidence rates of hepatotoxicity,
deaths, and deaths or new AIDS-defining events were
expressed as the number of patients with at least one
episode of the given event per 100 person-years of fol-
low-up. For the incidence rates as for the survival ana-
lyses, data were censored at the time of the first episode
of the given event. All analyses were performed using
STATA 10.01 software (STATA Corporation, college
Station, TX, USA).
Results
Patients
Of 169 HIV-1-infected patients enrolled between January
2001 and April 2003, 35 (21%) were coinfected with HBV
(n = 14) or HCV (n = 21). The baseline patient’s charac-
teristics are shown in table 1. Two thirds of patients were
women. Most patients were at an advanced HIV clinical
stage (42% were at the CDC stage B and 44% were at stage
C). The median CD4 count was 135 cells/mm
3 (interquar-
tile range [IQR] 67-218). Fifteen women (13%; 12 monoin-
fected with HIV and 3 coinfected with HBV or HCV) had
a CD4 count above 250 cells/mm
3.N om a nh a daC D 4
count above 400 cells/mm
3. Most characteristics were
similar between HIV-monoinfected patients and those
coinfected with an hepatitis virus. However, coinfected
patients were older (p < 0.001), and had higher liver
enzyme levels (p < 0.001). The median viral load was 2.47
×1 0
7 IU/mL for HBV (IQR 3680-1.59 × 10
8; range 270-
>2.2 × 10
8) and 928 000 IU/mL for HCV (IQR 178 400-
2.06 × 10
6; range 640-5.5 × 10
6) in patients coinfected
with the respective virus. The median time of follow-up
was 23.9 months (IQR 17.2-24.0) in monoinfected patients
and 24.0 months (IQR 20.0-24.0) in coinfected patients.
Half the patients received zidovudine, lamivudine and
nevirapine at baseline, and the other half received
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Page 3 of 11stavudine, lamivudine and nevirapine. Nevirapine was
interrupted during follow-up in 16 monoinfected patients
(12%) and 4 coinfected patients (11%) because of tubercu-
losis (n = 9 and 2, respectively), adverse effects (n = 4 and
2, respectively) and antiretroviral drug resistance (n = 3
and 0, respectively).
Hepatotoxicity
A total of 1588 measures of liver enzymes were avail-
able. The number of measures per patient was similar in
both infection groups (median 10, IQR 9-11, p =0 . 2 ) .
Two patients only (both were coinfected) had a grade 2
hepatotoxicity at baseline (90 IU/L and 97 IU/L,
Table 1 Baseline characteristics of patients by infection group
HIV monoinfected patients (n = 134) HBV or HCV coinfected patients (n = 35) p
Women (no.) 91 (68%) 22 (63%) 0.6
Age (years)
Median (IQR) 34.5 (28.4-39.7) 41.6 (33.7-48.8) <0.001
<42 (no.) 113 (84%) 19 (54%) <0.001
Time since diagnosis of HIV seropositivity (months)
Median (IQR) 29.4 (13.5-53.4) 22.1 (8.3-43.6) 0.2
<24 (no.) 56 (42%) 18 (51%) 0.3
Body weight (Kg) [median (IQR)] 65 (55-70) 63 (54-70) 0.7
Body mass index (Kg/m2)*
median (IQR) 23.2 (21.6-24.7) 22.2 (20.6-25.6) 0.2
≥ 21 (no.) 108 (82%) 25 (74%) 0.3
Karnofsky score >90% (no.) 72 (54%) 15 (43%) 0.3
CDC clinical stage (no.) 0.7
A 19 (14%) 4 (11%)
B 58 (43%) 13 (37%)
C 57 (43%) 18 (51%)
CD4 cell count (/mm3)
Median (IQR) 138 (67-222) 135 (68-216) 0.7
<100 (no.) 80 (60%) 22 (63%) 0.7
HIV-1 viral load (log10 copies/mL)
†
Median (IQR) 5.3 (4.7-5.5) 5.3 (4.8-5.7) 0.5
<5.0 (no.) 50 (37%) 11 (31%) 0.5
Hemoglobin (g/dL)
Median (IQR) 11.0 (9.8-12.1) 11.1 (9.8-12.9) 0.6
<10 (no.) 36 (27%) 10 (29%) 0.8
Total lymphocyte count (/mm3)
Median (IQR) 1578 (1080-2100) 1408 (1000-1900) 0.4
<1700 (no.) 77 (57%) 23 (66%) 0.4
ALT level (×ULN)
Median (IQR) 0.6 (0.4-0.7) 0.8 (0.6-1.2) <0.001
≥ 1.25 (no.) 8 (6%) 8 (30%) 0.002
ASAT (×ULN)
‡
Median (IQR) 0.8 (0.6-1.1) 1.3 (0.9-1.7) <0.001
≥ 1.25 (no.) 21 (17%) 17 (52%) <0.001
History of antiretroviral treatment (no.) 0.6
None 131 (98%) 34 (97%)
HAART 1 (1%) 1 (3%)
Nevirapine (PMTCT) 2 (2%) 0 -
Baseline antiretroviral treatment (no.) 0.3
Zidovudine+lamivudine+nevirapine 70 (52%) 15 (43%)
Stavudine+lamivudine+nevirapine 64 (48%) 20 (57%)
Cotrimoxazole prophylaxis (no.) 124 (93%) 35 (100%) 0.1
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal; PMTCT, prevention of mother-to-child transmission; HAART, highly
active antiretroviral therapy
* 3 missing values;
† 1 missing value;
‡ 9 missing values
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Page 4 of 11respectively); at week 2, hepatotoxicity dropped to grade
1 in one patient and remained at grade 2 in the other
patient. No patient had a baseline grade 3 or 4
hepatotoxicity.
During follow-up, 39 patients experienced at least one
episode of grade 2 or higher hepatotoxicity (22 monoin-
fected patients [16%] and 17 coinfected patients [49%]).
The corresponding incidence rate was 12.4 per 100 per-
son-years (95% confidence interval [CI] 8.2-18.9) in
monoinfected patients and 54.0 per 100 person-years
(CI 33.6-89.5) in coinfected patients. The Kaplan-Meier
analysis showed the higher risk in coinfected patients (p
< 0.001; figure 1). Of note, all episodes of hepatotoxicity
in the coinfected patients occurred in the first six
months. In monoinfected patients, such episodes
occurred throughout the follow-up (although more fre-
quently in the first months). In multivariate Cox analy-
sis, the risk of grade ≥ 2 hepatotoxicity remained higher
in coinfected patients (hazard ratio [HR] 2.94, CI 1.49-
5.81, p = 0.002; table 2) after adjustement on age (HR
0.90, CI 0.43-1.91, p = 0.8), Karnofsky score (HR 0.41,
CI 0.20-0.84, p = 0.01) and liver enzymes levels (HR
1.45, CI 0.74-2.82, p = 0.3). Of the 17 coinfected
patients who experienced a grade ≥ 2 hepatotoxicity, 4
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Figure 1 Proportion of patients who experienced episodes of grade ≥ 2 hepatotoxicity by infection group.
Table 2 Adjusted risks of outcomes associated with the hepatitis coinfection*
Outcome Ratio or coefficient 95% confidence interval p
Hepatotoxicity
Grade ≥2
† 2.94 1.49-5.81 0.002
Grade ≥3
† 2.18 0.61-7.75 0.2
Highest grade
‡ 1.83 1.28-2.60 0.001
CD4 cell count increase
||
Primary slope 0.02 -0.20 to 0.24 0.9
Secondary slope
¶ -0.04 -0.38 to 0.31 0.8
Quadratic effect
¶ 0.00 -0.00 to 0.01 0.8
Viral load < 400 copies/mL
† 1.00 0.68-1.47 0.9
Death
† 0.52 0.14-1.93 0.3
Death or new AIDS-defining event
† 0.37 0.11-1.29 0.1
* Coinfected patients versus monoinfected patients.
† Cox regression.
‡ Poisson regression.
|| Mixed-effect linear regression of the square root-transformed CD4
cell count.
¶ From 6 months to 24 months, combined with the primary slope.
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Page 5 of 11were positive for HBV (median viral load 1.80 × 10
8 IU/
mL, IQR 1.04 × 10
8-2.10 × 10
8) and 13 were positive for
HCV (median viral load 970 000 IU/mL, IQR 173 800-
2.06 × 10
6).
Only 12 patients (7%) experienced a grade 3 or 4
hepatotoxicity (7 monoinfected patients [5%] and 5
coinfected patients [14%]). The incidence rates were 3.6
(CI 1.7-7.6) and 9.9 per 100 person-years (CI 4.1-23.7)
in monoinfected and coinfected groups, respectively.
The risk tended to be higher in coinfected patients but
the difference was not significant (HR 2.18, CI 0.61-7.75,
p = 0.2; table 2) after adjustement on age (HR 1.28, CI
0.36-4.53, p = 0.8) and liver enzymes levels (HR 1.61, CI
0.47-5.46, p = 0.8). All 5 coinfected patients who experi-
enced a grade 3 or 4 hepatotoxicity were HCV positive;
their median viral load was 970 000 IU/mL (IQR 320
000-1.22 × 10
6).
The higher risk for hepatotoxicity in coinfected
patients was confirmed by the multivariate Poisson
regression analysis (incidence risk ratio [IRR] 1.83, CI
1.28-2.60, p = 0.001; table 2) after adjustement on age
(IRR 0.83, CI 0.56-1.24, p = 0.4) and Karnofsky score
(IRR 0.54, CI 0.39-0.76, p < 0.001).
Three patients developed ar a s hi nt h ef i r s tf o u r
weeks (two women with baseline CD4 counts of 31
and 307 cells/mm
3, respectively, and one man with a
baseline CD4 count of 18 cells/mm
3). Only the male
patient was coinfected (HBV viral load 4.88 × 10
7 IU/
mL). Nevirapine was replaced by a protease inhibitor
in all three patients. The woman with a high CD4 cell
count experienced simultaneously a grade 3 hepato-
toxicity. Nevirapine was also replaced by a protease
inhibitor in one other (monoinfected) patient with an
isolated grade 3 hepatotoxicity. No patient had clinical
hepatitis.
Immunological response
The number of CD4 cell counts per patient was com-
parable between the monoinfected group (median 5,
IQR 3-5) and the coinfected group (median 4, IQR 4-
5; p =0 . 5 ) .A ss h o w ni nf i g u r e2 A ,t h eC D 4c e l lc o u n t
increased after treatment initiation from 143 to 325
cells/mm
3 in monoinfected patients and from 136 to
297 cells/mm
3 in coinfected patients. The square root
CD4 cell count increase was not significantly different
between monoinfected and coinfected patients (either
in the first 6 months [p = 0.9] and thereafter [p =0 . 8 ] ;
table 2) after adjustement on gender (coefficient 1.59,
CI 0.41 to 2.77, p = 0.008), age (coefficient -1.07, CI
-2.43 to 0.29, p = 0.1), HIV-1 viral load (coefficient
1.55, CI 0.40 to 2.70, p = 0.008), hemoglobin level
(coefficient 2.43, CI 1.18 to 3.67, p < 0.001) and total
lymphocyte count (coefficient 2.93, CI 1.83 to 4.03, p <
0.001).
Virological response
The number of HIV-1 RNA measures per patient was
similar in both infection groups (median 5, IQR 4-6, p =
0.8). The proportion of patients with viral load below
400 copies/mL was 91% and 85% after 3 months and
91% and 78% after 24 months in monoinfected and
coinfected patients, respectively (figure 2B). The time
for reaching a viral load below 400 copies/mL did not
differ between the groups (HR 1.00, CI 0.68-1.47, p =
0.9; table 2). No other variable remained in the model.
Deaths or new AIDS-defining events
There were 16 deaths (12%) in monoinfected patients
and 3 (9%) in those coinfected. The mortality rates were
7.2 (CI 4.4-11.7) and 4.8 (CI 1.4-15.0) per 100 person-
years, respectively. The Kaplan-Meier curves did not dif-
fer significantly between the groups (p = 0.6, figure 3A).
In multivariate analysis, death was not associated with
coinfection (HR 0.52, CI 0.14-1.93, p = 0.3; table 2) after
adjustement on gender (HR 0.29, CI 0.11-0.77, p =
0.01), age (HR 1.90, CI 0.68-5.29, p = 0.2), CD4 cell
count (HR 0.15, CI 0.04-0.55, p =0 . 0 0 4 )a n dh e m o g l o -
bin level (HR 0.28, CI 0.11-0.74, p = 0.01). In the mono-
infected group, the deaths were related to advanced HIV
disease (n = 5), poor general health (n = 5), multifocal
tuberculosis, pulmonary infection, wasting, malaria, pan-
creatitis and hepatic carcinoma (n = 1 each). In the
coinfected group, death was related to advanced HIV
disease, poor general health and persistent fever of
unknown origin (n = 1 each); the first two patients had
taken traditional medicines.
Deaths or new AIDS-defining events occurred in 25
monoinfected patients (19%) and 5 coinfected patients
(14%). The respective incidence rates were 10.6 (CI 7.0-
16.1) and 6.7 per 100 person-years (CI 2.5-17.8). The
Kaplan-Meier curves showed no significant difference
between the groups (p = 0.5, figure 3B). In multivariate
analysis, the occurrence of deaths or new AIDS-defining
events was not associated with coinfection (HR 0.37, CI
0.11-1.29, p = 0.1; table 2) after adjustement on age (HR
1.33, CI 0.53-3.32, p = 0.5) and body mass index (HR
4.40, CI 1.98-9.78, p < 0.001).
Discussion
This study in Cameroon showed a higher hepatotoxicity
in HBV or HCV-coinfected patients receiving a nevira-
pine-based antiretroviral therapy than in their HIV-
monoinfected homologues. However, this adverse event
did not impact negatively on the effectiveness of
treatment.
Altogether, our analyses showed that the risk of hepa-
totoxicity was 2-fold higher in hepatitis B or C coin-
fected patients. This finding is consistent with previous
reports [11,17,27,28], especially with a study in patients
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Figure 2 Immunological and virological responses to antiretroviral therapy by infection group: mean CD4 cell count (A), and
percentage of patients with plasma HIV-1 viral load below 400 copies/mL (B). Bars indicate 95% confidence intervals.
Mbougua et al. BMC Public Health 2010, 10:105
http://www.biomedcentral.com/1471-2458/10/105
Page 7 of 11A 
0
.
0
0
0
.
2
5
0
.
5
0
0
.
7
5
1
.
0
0
P
r
o
p
o
r
t
i
o
n
 
o
f
 
d
e
a
t
h
s
0 3 6 12 18 24
Months
Monoinfected patients
Coinfected patients
B 
0
.
0
0
0
.
2
5
0
.
5
0
0
.
7
5
1
.
0
0
P
r
o
p
o
r
t
i
o
n
 
o
f
 
n
e
w
 
A
I
D
S
 
e
v
e
n
t
s
 
o
r
 
d
e
a
t
h
s
0 3 6 12 18 24
Months
Monoinfected patients
Coinfected patients
Number of patients         
Monoinfected 
patients         134  129  126  115 96 63
Coinfected  
patients           35  33  33  33 30 18
Number of patients         
Monoinfected 
patients         131  122  117  106 90 59
Coinfected  
patients           34  32  32  32 29 18
Figure 3 Clinical progression by infection group: progression to death (A), and progression to death or new AIDS-defining event (B).
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[29]. Of note, HCV-coinfected patients accounted for
76% of overall coinfected patients with liver enzymes
elevations >2.5 times the ULN (ALT and/or AST levels)
during treatment and 100% of those with liver enzymes
elevations >5 times the ULN (as compared with 60% of
the study’s coinfected group). It should however be
noted that HCV infection was not treated while HBV
infection was treated with lamivudine monotherapy.
Although anti-HBV lamivudine monotherapy has been
shown to lead to frequent emergence of drug resistance
[30] and, consequently, to possible acute hepatitis, ful-
minant hepatic failure, and death [3], lamivudine was
likely to be effective against HBV in the first months of
treatment when most episodes of hepatotoxicity
occurred. Importantly, up to half the coinfected patients
experienced liver enzymes elevations >2.5 times the
ULN.
Overall, the hepatic tolerability of the nevirapine-based
antiretroviral therapy was as expected. Seven percents of
patients experienced liver enzymes elevations >5 times
the ULN. In a comprehensive analysis of 17 randomized
clinical trials of nevirapine, the rate was 10% after one
year of treatment [31]. A higher rate of 17% has been
f o u n di nS o u t hA f r i c a np a t i e n t sw h oh a dam e a nb a s e -
line CD4 count of 398 cells/mm
3 [32]. Our lower rate
should be explained by the profound immunodeficiency
of our patients at the time of treatment initiation (med-
ian CD4 count of 135 cells/mm
3). Indeed, transaminases
elevations >5 times the ULN in patients receiving nevir-
apine has been associated with sex-dependant CD4 cell
count [5]. Thus, nevirapine should be avoided in women
with a CD4 count above 250 cells/mm
3 and in men
with a CD4 count above 400 cells/mm
3.I no u rs t u d y ,
only 13% of women and no man had a CD4 cell count
above these respective cuttoffs. Most transaminases ele-
vations in our patients were asymptomatic. Only 2% of
patients had a rash following treatment initiation. In
their analysis, Dieterich et al found a rash in 2.2% of
patients [31]. On the other hand, the incidence rates of
liver enzymes elevations >5 times the ULN in our
monoinfected and coinfected patients were comparable
to those reported in South African patients receiving an
efavirenz-based antiretroviral therapy [7].
The immunological response to the nevirapine-based
antiretroviral therapy was comparable between coin-
fected and monoinfected patients, in accordance with
several studies irrespective of the treatment prescribed
[7,11,13,14,18,20]. In contrast, other studies found
delayed CD4 cell count recovery in coinfected patients
especially in those coinfected with HCV [8-10,21]. How-
ever, this lower immunological response was not sus-
tained beyond the first few months in the Thai and
Swiss studies [10,33].
The virological response also was comparable between
patients coinfected with an hepatitis virus and patients
infected with HIV only. Increased risk for virological
failure has been reported in HBV-coinfected patients in
Taiwan [11]. However, most other studies like ours did
not find any difference [7,9,10,17,21].
The clinical progression did not differ significantly
between coinfected and monoinfected patients but treat-
ment was initiated late (median CD4 count of 135 cells/
mm
3). Surprisingly, deaths or new AIDS-defining events
were less common in coinfected patients. A possible
explanation could be a close medical supervision of
coinfected patients owing to frequent liver enzymes ele-
vations. Higher rates of deaths (from any cause, liver-
related causes and/or AIDS-related causes) and/or new
AIDS-defining events in patients coinfected with HBV
or HCV has been reported by some [8,11-16,18,20] but
not all studies [7,9,10,17]. In our study, only one death
was from a liver-related cause and this was recorded in
a monoinfected patient. Intake of traditional medicines
which have a potential for hepatic toxicity was however
reported in two of the three coinfected patients who
died.
T h em a i nl i m i t a t i o nt oo u rs t u d yw a st h er e l a t i v e l y
small sample size. However, a significant higher risk of
hepatotoxicity in coinfected patients was demonstrated.
Also, the absence of viral hepatitis impact on immuno-
logical and virological responses to antiretroviral therapy
was strongly suggested by the regression coefficients and
hazard ratio, respectively. Finally, the risk of clinical pro-
gression tended to decrease in coinfected patients which
is likely to be related to anu n m e a s u r e dc o n f o u n d i n g
factor. The exclusion of patients presenting with serum
liver enzyme levels higher than three or five times the
ULN values (depending on the initial study) could have
led to a selection bias (exclusion of patients with an
advanced hepatitis clinical stage) but this is concordant
with the recommendations for nevirapine use. Classifica-
tion biases for hepatitis status could also not be ruled
out because seronegative blood samples were not tested
f o rH B VD N Ao rH C VR N A .H i g h e rr a t e so fn e g a t i v e
HBsAg or anti-HCV results in viraemic samples have
been observed in immunocompromised HIV-infected
patients [3,4]. In addition, unrepeated testing of HBV
and HCV during follow-up did not allow to identify
new or reactivated hepatitis infections. New infections, if
any, were however likely to be rare owing to the study’s
duration and, for HBV, the usual childhood infections in
Africa through close contacts within households and, to
a lesser extent, vertical transmission (unclear modes of
transmission for HCV) [1]. On the other hand, no
symptomatic reactivated hepatitis infections were
recorded. In contrast, classification of patients on the
basis of HBV DNA and HCV RNA is clearly a strength
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gical assays.
Conclusion
This study suggests that the nevirapine-based antiretro-
viral therapy could be used safely as first-line treatment
in patients with low CD4 cell count in Africa despite
frequent coinfections with HBV or HCV and infrequent
testing of these infections. Although testing for HBV
and HCV should be systematically performed before
initiating antiretroviral therapy, transaminases elevations
at baseline or during treatment should be a decisive
argument for testing when hepatitis status is unknown.
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